Rapid and preemptive evaluation of individual anti-hepatitis C virus treatment outcome capability by a short-term autologous liver tissue culture system

Research output: Contribution to journalArticlepeer-review

Abstract

Hepatitis C virus (HCV) standard of care (SOC) therapy is not effective in a large percentage of patients and its efficacy may be evaluated only after several weeks. The aim of this work was to set up an in vitro liver culture assay able to preemptively predict SOC outcome by using residual liver samples from HCV patients. The in vitro response to SOC was found associated with the in vivo treatment outcome with a concordance of 100%. A wider clinical trial on a larger patient group is necessary to fully evaluate the impact of this procedure on the clinical management of untreated HCV patients.

Original languageEnglish
Pages (from-to)363-367
Number of pages5
JournalNew Microbiologica
Volume37
Issue number3
Publication statusPublished - 2014

Keywords

  • HCV standard therapy
  • In vitro HCV replication
  • In vitro tissue model
  • Liver biopsies

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Rapid and preemptive evaluation of individual anti-hepatitis C virus treatment outcome capability by a short-term autologous liver tissue culture system'. Together they form a unique fingerprint.

Cite this